Patents Assigned to Intra-Cellular Therapies, Inc.
  • Substituted pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity
    Patent number: 10072010
    Abstract: The invention relates to substituted pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]-quinoxaline compounds, represented by Formula 1, defined herein, free base or pharmaceutically acceptable salt forms of the compounds, pharmaceutical compositions thereof, and methods of treating conditions of the central nervous system therewith:
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: September 11, 2018
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Qiang Zhang, Robert Davis, Lawrence P. Wennogle
  • NOVEL METHODS
    Publication number: 20180200256
    Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
    Type: Application
    Filed: March 12, 2018
    Publication date: July 19, 2018
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Kimberly VANOVER, Peng LI, Sharon MATES, Robert DAVIS, Lawrence P. WENNOGLE
  • Organic compounds
    Patent number: 10010553
    Abstract: The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: July 3, 2018
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Allen A. Fienberg, Lawrence P. Wennogle, Sharon Mates
  • NOVEL USES
    Publication number: 20180177782
    Abstract: The invention relates to the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment of diseases or disorders characterized by disruption of or damage to various cGMP/PKG mediated pathways. In one embodiment the invention relates to inhibitors of phosphodiesterase 1 (PDE1) for treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.
    Type: Application
    Filed: September 19, 2017
    Publication date: June 28, 2018
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Lawrence P. Wennogle, Robert Davis
  • Organic compounds
    Patent number: 10005789
    Abstract: The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1), according to Formula I, below, wherein R1, R2, R3 and R4 are as defined herein, useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: June 26, 2018
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Hailin Zheng, Jun Zhao, Lawrence P. Wennogle
  • Method for the treatment of residual symptoms of schizophrenia
    Patent number: 9956227
    Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: May 1, 2018
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Kimberly Vanover, Peng Li, Sharon Mates, Robert Davis, Lawrence P. Wennogle
  • Organic compounds
    Patent number: 9944648
    Abstract: The invention provides novel compounds, composition comprising said compounds and methods for inhibiting CK1 as well as methods of treating CK1 related disorders such as Alzheimer's disease comprising administering a therapeutically effective amount of a CK1 inhibitor to a patient in need thereof.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: April 17, 2018
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Qiang Zhang, Youyi Peng, Peng Li, J. David Beard, Lawrence P. Wennogle, John Tomesch
  • Organic compounds
    Patent number: 9938284
    Abstract: The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1), useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: April 10, 2018
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Hailin Zheng, Jun Zhao, Lawrence P. Wennogle
  • SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS
    Publication number: 20180044337
    Abstract: The present invention provides methods for the preparation of substituted heterocycle fused gamma-carbolines, intermediates useful in producing them and methods for producing such intermediates and such heterocycl fused gamma-carbolines.
    Type: Application
    Filed: July 26, 2017
    Publication date: February 15, 2018
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: John Charles TOMESCH, Peng LI, Wei YAO, Qiang ZHANG, James David BEARD, Andrew S. THOMPSON, Hua CHENG, Lawrence P. WENNOGLE
  • Organic compounds
    Patent number: 9884872
    Abstract: Provided are PDE1 inhibitors of Formula I, processes for their production, their use as pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: February 6, 2018
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventor: Peng Li
  • NOVEL USES
    Publication number: 20180000825
    Abstract: The invention relates to the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment of diseases or disorders characterized by disruption of or damage to various cGMP/PKG mediated pathways. In one embodiment the invention relates to inhibitors of phosphodiesterase 1 (PDE1) for treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.
    Type: Application
    Filed: September 19, 2017
    Publication date: January 4, 2018
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Lawrence P. Wennogle, Robert Davis
  • Products and pharmaceutical compositions
    Patent number: 9849132
    Abstract: The present invention relates to a product comprising a PDE1 inhibitor and a PDE2 inhibitor, in free or salt form, pharmaceutical compositions comprising them and their use as pharmaceuticals for the treatment of cAMP and/or cGMP related disorders.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: December 26, 2017
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Joseph Hendrick, Jennifer O'Brien, Gretchen Snyder, Peng Li, Lawrence P. Wennogle
  • ORGANIC COMPOUNDS
    Publication number: 20170360792
    Abstract: The present invention relates to certain PDE2 inhibitory compounds, in free or salt form, pharmaceutical compositions containing such compounds and methods for the treatment of PDE2 mediated disorders.
    Type: Application
    Filed: December 7, 2015
    Publication date: December 21, 2017
    Applicant: Intra-Cellular Therapies, Inc.
    Inventors: Peng LI, Hailin ZHENG, Gretchen SNYDER, Lawrence P. WENNOGLE, Joseph HENDRICK
  • ORGANIC COMPOUNDS
    Publication number: 20170360753
    Abstract: The present invention relates to certain PDE2 inhibitory compounds, in free or salt form, pharmaceutical compositions containing such compounds and methods for the treatment of PDE2 mediated disorders.
    Type: Application
    Filed: December 7, 2015
    Publication date: December 21, 2017
    Applicant: Intra-Cellular Therapies, Inc.
    Inventors: Peng LI, Hailin ZHENG, Gretchen SNYDER, Lawrence P. WENNOGLE, Joseph HENDRICK
  • Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
    Patent number: 9801882
    Abstract: The invention relates to the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment of diseases or disorders characterized by disruption of or damage to various cGMP/PKG mediated pathways. In one embodiment the invention relates to inhibitors of phosphodiesterase 1 (PDE1) for treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: October 31, 2017
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Lawrence P. Wennogle, Robert Davis
  • ORGANIC COMPOUNDS
    Publication number: 20170283417
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D2 receptor signaling systems.
    Type: Application
    Filed: June 21, 2017
    Publication date: October 5, 2017
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng LI, Qiang ZHANG, Robert DAVIS, Lawrence P. Wennogle
  • PDE1 inhibitory compounds and methods
    Patent number: 9763948
    Abstract: Optionally substituted (1- or 3-oxy)-4,5,7,8-tetrahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine or (1- or 3-oxy)-4,5,7,8,9-pentahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-pyrimido[1,2-a]pyrrolo[3,4-e]pyrimidine compounds, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: September 19, 2017
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Jun Zhao
  • Preparation of certain [((6BR,10AS)-2,3,6B,7,8,9,10, 10A-octahydro-1H-pyrido[3?,4?:4,5]pyrrolo [1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereof
    Patent number: 9751883
    Abstract: The present invention provides methods for the preparation of substituted heterocycle fused gamma-carbolines of Formula 2J, as shown below, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines, such methods comprising the preparation of a Compound of Formula 2G, as shown below, and use of said compound to produce the fused gamma-carbolines of Formula 2J, as defined herein:
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: September 5, 2017
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: John Charles Tomesch, Peng Li, Wei Yao, Qiang Zhang, James David Beard, Andrew S. Thompson, Hua Cheng, Lawrence P. Wennogle
  • Organic compounds
    Patent number: 9745300
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: August 29, 2017
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Peng Li, Lawrence P. Wennogle, Robert Davis
  • ORGANIC COMPOUNDS
    Publication number: 20170231994
    Abstract: Provided are PDE1 inhibitors of Formula I, processes for their production, their use as pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: January 30, 2017
    Publication date: August 17, 2017
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng LI, Hailin ZHENG, Jun ZHAO, Lawrence P. WENNOGLE